Manulife (Manufacturers Life Insurance)
TRDA icon

Manulife (Manufacturers Life Insurance)’s Entrada Therapeutics TRDA Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$892K Buy
70,656
+14,111
+25% +$162K ﹤0.01% 1894
2025
Q4 		$572K Sell
56,545
-387
-0.7% -$3.26K ﹤0.01% 2117
2025
Q3 		$330K Buy
56,932
+1,108
+2% +$6.48K ﹤0.01% 2351
2025
Q2 		$375K Sell
55,824
-648
-1% -$5.21K ﹤0.01% 2290
2025
Q1 		$511K Sell
56,472
-85
-0.2% -$1.06K ﹤0.01% 2132
2024
Q4 		$978K Sell
56,557
-298
-0.5% -$5.4K ﹤0.01% 1919
2024
Q3 		$909K Sell
56,855
-243
-0.4% -$3.83K ﹤0.01% 1971
2024
Q2 		$814K Buy
57,098
+2,146
+4% +$30.5K ﹤0.01% 1960
2024
Q1 		$779K Sell
54,952
-723
-1% -$10.2K ﹤0.01% 1987
2023
Q4 		$840K Sell
55,675
-474
-0.8% -$7.02K ﹤0.01% 1886
2023
Q3 		$887K Hold
56,149
– – ﹤0.01% 1805
2023
Q2 		$850K Buy
56,149
+8,437
+18% +$116K ﹤0.01% 1746
2023
Q1 		$692K Buy
47,712
+6,506
+16% +$86.9K ﹤0.01% 1807
2022
Q4 		$582K Buy
41,206
+31
+0.1% +$543 ﹤0.01% 1892
2022
Q3 		$640K Hold
41,175
– – ﹤0.01% 1825
2022
Q2 		$532K Hold
41,175
– – ﹤0.01% 2019
2022
Q1 		$393K Buy
+41,175
New +$441K ﹤0.01% 2341

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s TRDA Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Entrada Therapeutics (TRDA) stake by 25% in Q1 2026, buying an estimated $162K and bringing the position to 70,656 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

Manulife (Manufacturers Life Insurance) first reported a position in TRDA in Q1 2022 and has held it in 17 quarters since. The position peaked at $978K in Q4 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 70,656 shares of Entrada Therapeutics worth $892K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 14,111 Entrada Therapeutics shares in Q1 2026, an estimated $162K.
  • Entrada Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1894 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Entrada Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Entrada Therapeutics position peaked at $978K in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.